EXOME: Biotech • Healthcare • Life Sciences

National
Bio Roundup: Grail Acquisition, Libra’s Launch, Tau Trial Results & More

Xconomy Awards On-Demand ‘Meet the Finalists’ Webcast Series Continues This Week

$96M

Monte Rosa Therapeutics

Silence Therapeutics Taps Orchard’s Mark Rothera as President & CEO

Synlogic Names Metera’s David Hava as Chief Scientific Officer

Tau-Targeting Alzheimer’s Drug from AC Immune, Roche Fails in Phase 2
Frank Vinluan | Europe
Athira CEO Kawas: Alzheimer’s Drug Aims for “Recovery of Brain Function”
Frank Vinluan | Seattle
Gene Therapy Firms Seek Clarity on FDA Exclusivity, Orphan Designations
Sue Sutter | National
Xconomy Awards On-Demand ‘Meet the Finalists’ Webcast Series Continues This Week
Editors | Boston
Illumina to Acquire Cancer Diagnostics Developer Grail in $8B Deal
Frank Vinluan | San Francisco
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
Frank Vinluan | National
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
Frank Vinluan | Boston
BIO Chief: “Reckless” Executive Order on Drug Prices Threatens Innovation
Dan Stanton | Boston
Finch Therapeutics Fetches $90M to Advance Microbiome Drug Pipeline
Frank Vinluan | Boston

Read More Posts ›

Underwriters and Partners

Xconomy Insight

Xconomy Insight · Special Report
How to Jump 5 Unforeseen Hurdles to Biotech Success – Startup Sourcebook
Insights, wisdom, and inspiration on what it takes

From Our Editors · Special Report
Xcelerating Life Sciences Philadelphia: Special Report
Becoming the Cell & Gene Therapy Hub

From Our Editors · Podcast
Xcelerating Life Sciences San Francisco: The Highlights Podcast
The AI, Big Data, and R&D Boom

Xconomy on Demand

We offer a number of ways to subscribe for free!